Exogenous lactate infusion (ELI) in traumatic brain injury: higher dose is better?

Paul Vespa, Stephanie M. Wolahan, Manuel Buitrago‐Blanco, Courtney Real, Jesus Ruiz-Tejeda, David L. McArthur, Jeffrey N. Chiang, Denes V. Agoston, Thomas C. GlennCritical 2025 · DOI

Traumatic brain injury (TBI) is not merely a structural event; it initiates a complex "metabolic crisis." Despite the availability of glucose, the injured brain often starves for fuel due to impaired glycolysis. This energy failure—characterized by a lack of pyruvate and a subsequent drop in ATP production—is a primary driver of secondary brain damage, high mortality, and poor functional recovery.

Recent research published in Critical Care (2025) suggests that the solution may lie in providing an alternative fuel source: lactate. However, the study highlights a critical nuance: the effectiveness of exogenous lactate infusion (ELI) appears to be strictly dose-dependent.

The Dosing Dilemma: Fixed vs. Precision Medicine

While the potential for lactate to bypass glycolytic bottlenecks has been recognized, clinical results have historically been inconsistent. The authors of this perspective paper hypothesized that previous failures might be attributed to underdosing. To test this, they compared traditional fixed-dose protocols with a new "precision medicine" approach designed to reach higher arterial lactate targets.

Figure 4: Comparison of Fixed vs. Precision Medicine ELI protocols and study timeline.

The study utilized a systematic review of 178 patients across nine historical studies alongside a new pilot cohort of five patients with severe TBI (GCS ≤ 8). As shown in the protocol comparison, the precision medicine arm targeted a blood lactate concentration of 4–6 mM, significantly higher than the 1.5–2 mM target used in fixed-dose arms. This was achieved through a weight-based initial infusion (4.5 mg/kg/min) followed by titration every 15 minutes based on point-of-care measurements.

Achieving the Metabolic "Sweet Spot"

The pilot study demonstrated that the precision titration protocol could reliably and safely maintain the target 4–6 mM range. This range appears to be the metabolic "sweet spot" required to trigger significant neuroprotective shifts.

Figure 5: Mean arterial lactate levels achieved in the Precision Medicine high-dose arm over a 3-hour infusion.

In contrast to lower doses, the high-dose precision protocol resulted in several key physiological improvements:

  • Restored Oxidative Metabolism: High-dose ELI led to an 8% increase in SOD 2 (Superoxide Dismutase 2), a marker indicating that the brain was actively utilizing the infused lactate to restore mitochondrial energy production.
  • Intracranial Pressure (ICP) Control: The high-dose arm saw a statistically significant reduction in ICP (decreasing at a rate of 1.2 mm Hg/hr), a benefit not consistently observed in historical low-dose cohorts.
  • Reduction in Injury Biomarkers: Molecular analysis via Reverse Phase Protein Microarray (RPPM) revealed significant decreases in markers of programmed cell death (Caspase 9) and neuronal injury (UCH-L1).

Mechanisms of Neuroprotection

The study suggests that lactate acts as both a signaling molecule and a direct fuel source. By providing the brain with a substrate that bypasses impaired glycolysis, high-dose ELI helps stabilize cellular energy levels. The observed reduction in ICP may be a secondary benefit of this improved metabolism or a result of the osmotic effect of sodium lactate, similar to the action of hypertonic saline.

Conclusion and Future Directions

While the pilot cohort was small (n=5), it serves as a robust proof-of-concept for high-dose, titrated lactate therapy. The precision medicine protocol successfully reached therapeutic targets without adverse effects like pulmonary edema or dangerous pH shifts.

Future research must now determine if these metabolic improvements translate into long-term functional recovery. Key questions remain regarding the optimal duration of infusion—whether extending the treatment beyond three hours could offer cumulative benefits—and the exact balance between the metabolic and osmotic effects of the infusion. Nonetheless, this study marks a significant step toward a more targeted, bioenergetic approach to treating severe brain injury.

Summary updated

Abstract

ClinicalTrials.gov ID NCT02776488. Date registered: 2016-05-17. Retrospectively Registered.
BibTeX
@inproceedings{vespa2025exogenous,
  author = {Paul Vespa and Stephanie M. Wolahan and Manuel Buitrago‐Blanco and Courtney Real and Jesus Ruiz-Tejeda and David L. McArthur and Jeffrey N. Chiang and Denes V. Agoston and Thomas C. Glenn},
  title = {{Exogenous lactate infusion (ELI) in traumatic brain injury: higher dose is better?}},
  booktitle = {Critical},
  year = {2025},
  doi = {10.1186/s13054-025-05374-y},
}
Figure